Surface Oncology, Inc.
DelistedCIK 1718108fmd_0G2YS4WB0X088BEY1P3Q82EBPGManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Jun 30, 2023, 27 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Total revenues | 7 | 13 | 59 | 15 | 126 | 3 | 30 |
| Research and development | 20 | 48 | 52 | 52 | 41 | 54 | 67 |
| Total operating expenses | 25 | 59 | 69 | 73 | 65 | 79 | 92 |
| Operating income | (18) | (46) | (9) | (57) | 62 | (76) | (62) |
| Interest expense | – | – | – | 0 | 3 | 3 | 3 |
| Other non-operating income (expense) | – | – | – | 3 | 1 | 0 | 1 |
| Income before taxes | – | (45) | (7) | (55) | 59 | (78) | (64) |
| Net income | (17) | (45) | (7) | (55) | 59 | (78) | (64) |
| Net income to common shareholders | – | – | (7) | (55) | 59 | (78) | (64) |